Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
NCT: NCT04065490 · COMPLETED
Publicidad
Resumen breve
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. Alcon Research, LLC, acquired LumiThera in September 2025.
Fuente oficial
Ver en ClinicalTrials.gov →Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.